Fulgent Genetics, Inc.
FLGT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2.8% | 11.4% | -3.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 42.2% | 42.1% | 38.6% | 41.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -18.3% | -24.1% | -26.9% | -21.2% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7.9% | -23.2% | -15.7% | -7.7% |
| EPS | -0.21 | -0.61 | -0.37 | -0.19 |
| % Growth | 65.6% | -64.9% | -94.7% | – |
| EPS Diluted | -0.21 | -0.61 | -0.37 | -0.19 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -0.1% | -18.9% | -7.9% | -13% |